NCT07103395View on ClinicalTrials.gov

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Lung Cancer (NSCLC)
Interventions
DRUG

Neoadjuvant therapy

The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.

RADIATION

Radiotherapy

Definitive dose of hypofractionated radiotherapy was delivered to patients, with concurrent chemotherapy.

DRUG

Consolidative therapy

Consolidation therapy consists of iparomlimab and tuvonralimab and thymosin alpha 1, for a total duration of 1 year.

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER